557 related articles for article (PubMed ID: 28942246)
1. Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4/NOX1-mediated regulation of superoxide.
Long Z; Cao M; Su S; Wu G; Meng F; Wu H; Liu J; Yu W; Atabai K; Wang X
Free Radic Biol Med; 2017 Dec; 113():71-83. PubMed ID: 28942246
[TBL] [Abstract][Full Text] [Related]
2. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.
Baumeier C; Schlüter L; Saussenthaler S; Laeger T; Rödiger M; Alaze SA; Fritsche L; Häring HU; Stefan N; Fritsche A; Schwenk RW; Schürmann A
Mol Metab; 2017 Oct; 6(10):1254-1263. PubMed ID: 29031724
[TBL] [Abstract][Full Text] [Related]
3. NADPH oxidase 1 promotes hepatic steatosis in obese mice and is abrogated by augmented skeletal muscle mass.
Larion S; Padgett CA; Mintz JD; Thompson JA; Butcher JT; Belin de Chantemèle EJ; Haigh S; Khurana S; Fulton DJ; Stepp DW
Am J Physiol Gastrointest Liver Physiol; 2024 Mar; 326(3):G264-G273. PubMed ID: 38258487
[TBL] [Abstract][Full Text] [Related]
4. Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice.
Li Y; Zalzala M; Jadhav K; Xu Y; Kasumov T; Yin L; Zhang Y
Hepatology; 2016 Jun; 63(6):1860-74. PubMed ID: 26806650
[TBL] [Abstract][Full Text] [Related]
5. The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease.
Matsumoto M; Zhang J; Zhang X; Liu J; Jiang JX; Yamaguchi K; Taruno A; Katsuyama M; Iwata K; Ibi M; Cui W; Matsuno K; Marunaka Y; Itoh Y; Torok NJ; Yabe-Nishimura C
Free Radic Biol Med; 2018 Feb; 115():412-420. PubMed ID: 29274380
[TBL] [Abstract][Full Text] [Related]
6. Oleanolic acid attenuates PCBs-induced adiposity and insulin resistance via HNF1b-mediated regulation of redox and PPARγ signaling.
Su S; Wu G; Cheng X; Fan J; Peng J; Su H; Xu Z; Cao M; Long Z; Hao Y; Li G; Li S; Hai C; Wang X
Free Radic Biol Med; 2018 Aug; 124():122-134. PubMed ID: 29879443
[TBL] [Abstract][Full Text] [Related]
7. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
8. Polychlorinated biphenyls-153 induces metabolic dysfunction through activation of ROS/NF-κB signaling via downregulation of HNF1b.
Wu H; Yu W; Meng F; Mi J; Peng J; Liu J; Zhang X; Hai C; Wang X
Redox Biol; 2017 Aug; 12():300-310. PubMed ID: 28285191
[TBL] [Abstract][Full Text] [Related]
9. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H
J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216
[TBL] [Abstract][Full Text] [Related]
10. A siRNA mediated hepatic dpp4 knockdown affects lipid, but not glucose metabolism in diabetic mice.
Görgens SW; Jahn-Hofmann K; Bangari D; Cummings S; Metz-Weidmann C; Schwahn U; Wohlfart P; Schäfer M; Bielohuby M
PLoS One; 2019; 14(12):e0225835. PubMed ID: 31794591
[TBL] [Abstract][Full Text] [Related]
11. Maresin 1 attenuates NAFLD by suppression of endoplasmic reticulum stress via AMPK-SERCA2b pathway.
Jung TW; Kim HC; Abd El-Aty AM; Jeong JH
J Biol Chem; 2018 Mar; 293(11):3981-3988. PubMed ID: 29414781
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6.
Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J
Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567
[TBL] [Abstract][Full Text] [Related]
13. Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.
Cai X; Fang C; Hayashi S; Hao S; Zhao M; Tsutsui H; Nishiguchi S; Sheng J
J Gastroenterol; 2016 Aug; 51(8):819-29. PubMed ID: 26794005
[TBL] [Abstract][Full Text] [Related]
14. Impact of glycosylphosphatidylinositol-specific phospholipase D on hepatic diacylglycerol accumulation, steatosis, and insulin resistance in diet-induced obesity.
Masuda S; Fujishima Y; Maeda N; Tsugawa-Shimizu Y; Nakamura Y; Tanaka Y; Obata Y; Fukuda S; Nagao H; Kita S; Nishizawa H; Shimomura I
Am J Physiol Endocrinol Metab; 2019 Feb; 316(2):E239-E250. PubMed ID: 30457913
[TBL] [Abstract][Full Text] [Related]
15. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice.
Xiong X; Wang X; Lu Y; Wang E; Zhang Z; Yang J; Zhang H; Li X
J Hepatol; 2014 Apr; 60(4):847-54. PubMed ID: 24333182
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease.
Xu M; Zheng XM; Jiang F; Qiu WQ
J Cell Biochem; 2018 Jul; 119(7):5864-5874. PubMed ID: 29575055
[TBL] [Abstract][Full Text] [Related]
17. Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models.
Kim MK; Chae YN; Ahn GJ; Shin CY; Choi SH; Yang EK; Sohn YS; Son MH
Arch Pharm Res; 2017 Feb; 40(2):268-281. PubMed ID: 27885461
[TBL] [Abstract][Full Text] [Related]
18. Thromboxane A2/thromboxane A2 receptor axis facilitates hepatic insulin resistance and steatosis through endoplasmic reticulum stress in non-alcoholic fatty liver disease.
Dai Y; Xu R; Chen J; Fang J; Zhang H; Li H; Chen W
Br J Pharmacol; 2024 Apr; 181(7):967-986. PubMed ID: 37940413
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.
Wu GY; Rui C; Chen JQ; Sho E; Zhan SS; Yuan XW; Ding YT
Cell Physiol Biochem; 2017; 44(4):1651-1664. PubMed ID: 29216638
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
